ORYZON Files Clinical Trial Application in Spain for Phase I Study with ORY-2001 for Alzheimer’s Disease
2015-12-16 · Oryzon Genomics S.A. · original oryzon.com ↗
16 December 2015 ORYZON Files Clinical Trial Application in Spain for Phase I Study with ORY-2001 for Alzheimer’s Disease BARCELONA, SPAIN and CAMBRIDGE MA. Oryzon Genomics - ORY (ISIN Code: ES0167733015), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, today announced that a Clinical Trial Application (CTA), the European IND equivalent, has been filed with the Spanish Drug Agency (AEMPS) to conduct a Phase I clinical study with healthy volunteers as a first step to determine the potential of ORY-2001 for the treatment of Alzheimer’s disease (AD). Click here to see the full Press Release
The release as fetched from its publisher. oryzon.com ↗